Novartis' Deal With Thais Averts License Battle

Law360, New York (February 4, 2008, 12:00 AM EST) -- Sidestepping a potential high-profile battle over compulsory licensing, Swiss pharmaceutical giant Novartis AG has agreed to provide its cancer drug Glivec free of charge to most patients in Thailand.

Thailand’s government abandoned its plans to issue a compulsory license for the patented drug after Novartis agreed to supply free Glivec to all patients with a household income of less than 1.7 million baht (U.S. $51,515) per year under the Glivec International Patient Assistance Programme, the Bangkok Post reported Sunday.

Novartis, which has been locked in negotiations...
To view the full article, register now.